Company Overview - Founded in 2003, the company launched its first multi-channel sleep monitor in 2003 and its first CPAP sleep breathing machine in 2007. It received CE certification in 2008 and FDA certification in 2012, with successful listing on the Shenzhen Stock Exchange in 2016 [2][3]. - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management, and is a leading domestic manufacturer of non-invasive ventilators and masks [2][3]. Product and Market Development - As of June 30, 2025, the company holds 666 valid domestic patents, including 116 invention patents, 404 utility model patents, and 146 design patents. It also has 266 overseas patents, including 45 in the U.S. and 38 in Europe [3]. - The G3 X model non-noise cotton ventilator has received FDA approval and is now eligible for sale in the U.S. market, with sales commencing in July 2025 [4]. - The company has established a European cloud platform, facilitating the transition from non-mainstream to mainstream insurance markets, which supports sustainable development in Europe [5]. Financial Performance - The company has seen a continuous improvement in gross margin, attributed to effective cost control and an increase in the proportion of high-margin consumables [6]. - The company has achieved significant localization in its supply chain, ensuring domestic supply chain safety and cost advantages [7]. Competitive Advantages - The company has a deep understanding of global medical device regulations and a well-established distribution network, having entered major insurance markets in the U.S., Germany, the U.K., France, and Italy [7]. - It has a professional intellectual property department, securing patents and trademarks in key global markets, which strengthens its overseas market position [7]. - Since 2023, the company has focused on localizing its operations and hiring international talent to enhance its global operational capabilities [7].

Core Viewpoint - BMC瑞迈特 actively participates in international standard verification to promote high-quality development in the medical technology industry, showcasing its technical strength and global vision through expanded international testing capabilities [1][4]. Group 1: International Standard Verification - BMC瑞迈特's subsidiary, Tianjin Yihe Jiaye Medical Technology Co., Ltd., recently passed the CNAS accreditation extension review, further expanding its international testing scope [1]. - The company aims to unify global non-invasive respiratory device testing boundaries and establish internationally recognized technical indicators and criteria [1][4]. - BMC瑞迈特 has contributed to the clarity and enforceability of international standards through practical feedback during the standard-setting process [2]. Group 2: Specific Contributions to Standards - In May 2023, BMC瑞迈特 experts defined the starting point for dynamic pressure sampling in the international standard for sleep apnea treatment devices, which was adopted by the international standard committee, enhancing comparability of test results globally [2]. - The team proposed a solution to extend the global applicable temperature range for respiratory humidification devices, which was accepted by the ISO working group, ensuring device performance in diverse environments [3]. - BMC瑞迈特 recommended a standardized testing distance of 1 meter for noise level measurements in oxygen concentrators, resolving inconsistencies in global noise claims and promoting fair trade [3]. Group 3: Global Quality Assurance Network - BMC瑞迈特 has established a global quality assurance network covering research and development, manufacturing, and market access, enhancing its global technical capabilities and influence [4]. - The company collaborates with CNAS to ensure consistent testing across production bases and to meet international market requirements [4]. - By participating in international standard verification, BMC瑞迈特 strengthens its global voice and facilitates efficient market access for its products [4].

Core Viewpoint - 瑞迈特医疗科技股份有限公司 has shown a significant increase in stock price, indicating positive market sentiment and potential growth in the respiratory health sector [1] Company Overview - 瑞迈特医疗科技股份有限公司, established on July 27, 2001, and listed on November 1, 2022, specializes in the research, production, and sales of medical devices and consumables in the respiratory health field [1] - The company provides comprehensive treatment solutions for patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD), covering the entire cycle from diagnosis to chronic disease management [1] - The revenue composition of the company includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Fund Holdings - 华泰柏瑞基金旗下 has a significant holding in 瑞迈特, with 华泰柏瑞价值增长混合A (460005) holding 136,900 shares, representing 1.64% of the fund's net value, ranking as the tenth largest holding [2] - The fund has achieved a year-to-date return of 42.98% and a one-year return of 50.61%, indicating strong performance relative to its peers [2] Fund Manager Profile - The fund manager of 华泰柏瑞价值增长混合A is 方纬, who has been in the position for nearly 12 years, managing assets totaling 2.127 billion yuan [3] - During his tenure, the best fund return achieved was 260.51%, showcasing effective management skills [3]

Core Viewpoint - On October 10, 2023, Ruimait experienced a 2.91% increase in stock price with a trading volume of 123 million yuan, indicating positive market sentiment towards the company [1]. Financial Performance - For the first half of 2025, Ruimait achieved a revenue of 544 million yuan, representing a year-on-year growth of 42.30%. The net profit attributable to shareholders was 131 million yuan, also reflecting a growth of 42.19% [2]. - Cumulative cash dividends distributed by Ruimait since its A-share listing amount to 228 million yuan [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders in Ruimait decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [2]. - On October 10, 2023, Ruimait's financing buy-in amounted to 12.20 million yuan, with a net buy of 3.00 million yuan, indicating strong investor interest [1]. - The total balance of margin trading for Ruimait reached 109 million yuan, accounting for 2.25% of its market capitalization, which is above the 50th percentile level over the past year [1]. Business Overview - Ruimait, established on July 27, 2001, specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The revenue composition of Ruimait includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders of Ruimait [3].

股票简称：瑞迈特 股票代码：301367 北京瑞迈特医疗科技股份有限公司 简式权益变动报告书 上市公司名称：北京瑞迈特医疗科技股份有限公司 股票上市地：深圳证券交易所 信息披露义务人（一）：能金有限公司 住所或通讯地址：香港，九龙，旺角，亚皆老街109号，皆旺商业大厦22楼 2室 信息披露义务人（二）：广州市金垣创业投资合伙企业（有限合伙） 住所或通讯地址：广州市黄埔区国际生物岛螺旋四路5号（2）栋第三层309、 310单元 股份变动性质：持股比例降至 5%以下 签署日期：2025年10月9日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理 办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报 告书》及其他相关法律法规和部门规章的有关规定编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发 行证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定， 本报告书已全面披露信息披露义务人在瑞迈特中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的持股信 ...

证券代码：301367 证券简称：瑞迈特 公告编号：2025-060 北京瑞迈特医疗科技股份有限公司 关于持股5%以上股东及其一致行动人减持至5%以 下的权益变动暨减持计划届满实施情况的公告 公司股东能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限 合伙）、珠海合晅投资中心（有限合伙）及其一致行动人上海盛旻创业投资合伙 企业（有限合伙）和南京合灏创业投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次权益变动后，股东能金有限公司（以下简称"能金公司"）及其一 致行动人广州市金垣创业投资合伙企业（有限合伙）（以下简称"广州金垣"） 持有北京瑞迈特医疗科技股份有限公司（以下简称"公司"）股份 4,479,120 股， 占本公司总股本的 4.9990%，持股比例下降至 5%以下，不再是公司持股 5%以上 股东。 2、本次权益变动属于股份减持，不触及要约收购，不会导致公司控股股东、 实际控制人发生变化。 北京瑞迈特医疗科技股份有限公司（以下 ...

北京瑞迈特医疗科技股份有限公司 章 程 2025 年 | | | | 第一章 | 总则 1 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 | 股份 3 | | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东会 | 7 | | 第一节 | 股东的一般规定 | 7 | | 第二节 | 控股股东和实际控制人 10 | | | 第三节 | 股东会的一般规定 | 11 | | 第四节 | 股东会的召集 | 17 | | 第五节 | 股东会的提案与通知 | 18 | | 第六节 | 股东会的召开 | 20 | | 第七节 | 股东会的表决和决议 | 23 | | 第五章 | 董事会 27 | | | 第一节 | 董事的一般规定 | 27 | | 第二节 | 董事会 | 31 | | 第三节 | 独立董事 | 38 | | 第四节 | 董事会专门委员会 41 | | | 第六章 | 高级管理人员 | 43 | | 第七章 | 财务会计制度、利润分配和审计 | 45 | ...

关于修改经营范围、修订《公司章程》、完成工商变更登记 并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京瑞迈特医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开第三届董事会第十五次会议、于 2025 年 9 月 16 日召开 2025 年第二次临 时股东会，审议通过了《关于修改公司经营范围、修订<公司章程>、制定及修 订部分公司制度的议案》。 一、基本情况 根据《公司法》《证券法》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上市 公司独立董事管理办法》等相关法律、法规和规范性文件，为进一步完善公司治 理结构，促进规范运作，并结合公司自身实际情况，修改公司经营范围、修订《公 司章程》、制定及修订部分公司制度。其中公司拟调整三会结构，将不再设置监 事会，《公司法》规定的监事会的职权由公司董事会审计委员会行使。具体内容 详见 2025 年 8 月 28 日公司披露于巨潮资讯网（www.cninfo.com.cn）等指定媒体 的《关于修改公司经营范 ...

Group 1 - The company's performance met expectations with a steady increase in gross margin, achieving revenue of 544 million yuan in the first half of 2025, a year-on-year growth of 42.3%, and a net profit attributable to shareholders of 131 million yuan, also up 42.19% [1] - The consumables segment experienced rapid growth, generating revenue of 178 million yuan in the first half of 2025, reflecting a year-on-year increase of 30.26%. The company has been actively expanding its international market presence, particularly in the U.S. since 2023 through a specialized team established by RH [1] - The company's overseas business continues to advance, with global market position steadily improving. In the first half of 2025, overseas revenue reached 353 million yuan, marking a year-on-year growth of 61.33%. According to data from Sullivan, the company's market share for home non-invasive ventilators was significant in 2023 [1] Group 2 - Revenue forecasts for the company are projected at 1.013 billion yuan, 1.268 billion yuan, and 1.610 billion yuan for the years 2025 to 2027, with corresponding EPS of 2.60 yuan, 3.35 yuan, and 4.47 yuan. The current stock price corresponds to PE ratios of 31.5, 24.4, and 18.3 times respectively, indicating a leading market position in ventilators and consumables [1]

Core Insights - The company achieved revenue of 544 million yuan in the first half of 2025, representing a year-on-year growth of 42.3%, with a net profit of 131 million yuan, also up by 42.19% [1] - The gross margin has shown a steady increase, with figures of 46.14%, 48.34%, and 52.17% for the years 2023, 2024, and the first half of 2025 respectively [1] Group 1: Revenue and Profit Growth - The company reported a revenue of 544 million yuan in H1 2025, a 42.3% increase year-on-year [1] - The net profit for the same period was 131 million yuan, reflecting a growth of 42.19% [1] - The gross margin has consistently improved, reaching 52.17% in H1 2025 [1] Group 2: International Market Expansion - The consumables segment generated revenue of 178 million yuan in H1 2025, marking a 30.26% increase [2] - The company has been actively promoting its consumables in the U.S. market since 2023 through a specialized team [2] - In Europe, a subsidiary was established in France in 2023 to enhance market coverage and attract more partnerships [2] Group 3: Global Market Position - The company's overseas revenue reached 353 million yuan in H1 2025, a significant increase of 61.33% [3] - The company holds a 12.4% market share in the global home non-invasive ventilator market, ranking second, while leading with a 30.6% share in the domestic market [3] - The company is projected to achieve revenues of 1.013 billion yuan, 1.268 billion yuan, and 1.610 billion yuan for the years 2025, 2026, and 2027 respectively [3]